Description
Breast cancer is the most common cancer in Canadian women, accounting for an estimated 26 per cent of all cancer cases at the time of publication. Gene expression profiling (GEP) is an emerging technology that may be able to successfully divide breast cancer patients into prognostic groups based on genes that increase in proliferating cells. Oncotype DX (Genome Health Inc.) is one commercially available GEP in Canada. However, there are concerns about the value-added merit of this testing. The primary policy question to be answered by this report is: Should Oncotype DX be publicly funded in Alberta? Other research objectives of the study include: determining the safety and effectiveness/efficacy of Oncotype DX as a decision support tool for adjuvant chemotherapy treatment decisions in women with early stage invasive breast cancer; determining the cost-effectiveness of Oncotype DX and other relevant comparators, and determining the budget impact of Oncotype DX as a decision support tool for adjuvant chemotherapy treatment decisions.
Updated
August 7, 2013
Tags
Title and publication information
Type
Extent
113 pages
Frequency
Once
Publisher / Creator Information
Creator
Publisher
non-Government of Alberta entity
Place of Publication
Subject Information
Topic
Subject (LCSH)
Subject (LCSH)
Subject (LCSH)
Subject (LCSH)
Subject (LCSH)
Subject (LCSH)
Resource Dates
Date Created
2013-08-07
Date Added
2017-07-07T16:56:16.640440
Date Modified
2013-08-07
Date Issued
2013-08-07
Audience information
Language
Identifiers
NEOS catalogue key
6992977
Usage / Licence
Usage Considerations
- Health technology assessment reports were produced by partner organizations for Alberta Health and the Alberta Health Technologies Decision Process. The conclusions presented in the reports are solely those of the partner organization that produced the reports and do not represent the policies or position of the Government of Alberta, Alberta Health, or any other agency.
- Page 2: Supported by a financial contribution from Alberta Health through the Alberta Health Technologies Decision Process; the Alberta model for health technology assessment and policy analysis.